TNF and juvenile idiopathic arthritis: Two classes of recombinant TNFi are currently used in the treatment of JIA: TNF receptor fusion proteins (e.g., etanercept) and monoclonal anti-TNF antibodies (adalimumab, certolizumab pegol, golimumab, and infliximab), and some related biosimilars [13–21].